Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025

blonca9
Dec 18, 2024
1 min read

Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha Gene Therapies, and more.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight